The launch of the European Institute for innovation through health data
Journal Title: Journal of Medicines Development Sciences - Year 2016, Vol 2, Issue 2
Abstract
The European Institute for Innovation through Health Data (i~HD) has been formed as one of the sustainable entities arising from the Electronic Health Records for Clinical Research (EHR4CR) and SemanticHealthNet projects, in collaboration with other European Commission projects and initiatives. The vision of i~HD is to become the European organisation of reference for guiding and catalysing the best, most efficient and trustworthy uses of health data and interoperability, for optimizing health and knowledge discovery. i~HD has been established in recognition that there is a need to tackle areas of challenge in the successful scaling up of innovations that rely on high-quality and interoperable health data, to sustain and propagate the results of eHealth research, and to address current-day obstacles to using health data. i~HD was launched at an inaugural conference in Paris, in March 2016. This was attended by over 200 European clinicians, healthcare providers and researchers, representatives of the pharma industry, patient associations, health professional associations, the health ICT industry and standards bodies. The event showcased issues and approaches, that are presented in this paper to highlight the activities that i~HD intends to pursue as enablers of the better uses of health data, for care and research.
Authors and Affiliations
Dipak Kalra, Mats Sundgren, Brecht Claerhout, Pierre Meulien, Bart Vannieuwenhuyse,Peter Singleton, Terje Peetso, Veli Stroetmann, Petra Wilson, Mary Baker,Pascal Coorevits, John O’Brien, Georges De Moor
Keywords
Related Articles
- EP ID EP679238
- DOI -
- Views 190
- Downloads 0
TransCelerate: a global collaboration across biopharmaceutical R&D to accelerate and simplify new medicines development
As the economic pressures increase on healthcare systems around the world due to aging populations, chronic diseases, expanding patient populations in emerging markets and advances in medical technology, it is crucial th...
HDL therapies — past, present and future
For a number of years, high-density lipoprotein (HDL) has been recognized to have an athero-protective role by promoting reverse lipid transport, a process facilitating the cholesterol efflux from atherosclerotic plaques...
Open innovation to bolster research and development for neglected and emerging infectious diseases
Infections remain a significant cause of disease, disability, and death in developing countries. Unfortunately, many of these infections, including centuries-old neglected diseases such as malaria and newly emerging and...
Japanese initiative for education in pharmaceutical medicine and clinical research training
Development of new medicines has become increasingly difficult with less possibility of success in seeds-finding and ever rising operational costs. Failure to comply with ethical standards for human research protection a...
Role of the P2Y6 receptor of UDP in the modulation of murine dendritic cell functions and Th1 polarisation of the immune response
Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y6 receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y6 receptor in the adaptive immune respons...